Antitumor Compound Testing in Glioblastoma Organotypic Brain Cultures

T Biggs, J Foreman, LE Sundstrom, U Regenass, F Lehembre

Research output: Contribution to journalArticle (Academic Journal)peer-review

11 Citations (Scopus)


Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumor. Identification of new therapeutic regimens is urgently needed. A major challenge remains the development of a relevant in vitro model system with the necessary capacity and flexibility to profile compounds. The authors have developed and characterized a 3D culture system of brain cells (brain Hi-Spot) where GBM-derived cells can be incorporated (GBM/brain Hi-Spot). Immuno-fluorescence and electrophysiological recordings demonstrate that brain Hi-Spots recapitulate many features of brain tissue. Within this tissue, GBM-derived cell growth is monitored using a fluorescence assay. GBM-derived cells growing in Hi-Spots form tumor nodules that display properties of GBM such as 5-Ala positive staining, an acidic environment, and tumor-surrounding astrocyte activation. Temozolomide inhibits GBM growth in brain Hi-Spots, but it is not effective in 2D cultures. Other chemotherapeutics that have proven to be inefficient in GBM treatment display low activity against GBM-derived cells growing in brain Hi-Spots in comparison to their activity against GBM 2D cultures. These findings suggest that GBM/brain Hi-Spots represent a simple system to culture cells derived from brain tumors in an orthotopic environment in vitro and that the system is reliable to test GBM targeting compounds.
Translated title of the contributionAntitumor Compound Testing in Glioblastoma Organotypic Brain Cultures
Original languageEnglish
Pages (from-to)805 - 817
Number of pages3
JournalJournal of Biomolecular Screening
Publication statusPublished - Sep 2011


Dive into the research topics of 'Antitumor Compound Testing in Glioblastoma Organotypic Brain Cultures'. Together they form a unique fingerprint.

Cite this